{"nctId":"NCT00154284","briefTitle":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","startDateStruct":{"date":"2005-07"},"conditions":["Organ Transplantation, Renal Transplantation"],"count":114,"armGroups":[{"label":"Everolimus (Certican) with Cyclosporine (Neoral) Continuation","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus (Certican)","Drug: Cyclosporine (Neoral)","Drug: Steroid","Drug: Basiliximab (Simulect)"]},{"label":"Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus (Certican)","Drug: Cyclosporine (Neoral)","Drug: Steroid","Drug: Basiliximab (Simulect)"]}],"interventions":[{"name":"Everolimus (Certican)","otherNames":["Certican"]},{"name":"Cyclosporine (Neoral)","otherNames":["Neoral"]},{"name":"Steroid","otherNames":["Prednisone"]},{"name":"Basiliximab (Simulect)","otherNames":["Simulect"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Recipients of a first renal transplant from a primary cadaveric or non-HLA identical living related donor.\n* Renal cold ischemic time \\< 36 hours.\n* Age of donor \\< 65 years.\n\nExclusion Criteria:\n\n* Patients who have received an investigational drug within 4 weeks of baseline period.\n* Patients who are recipients of multiple organ transplants, including any organ other than kidney.\n* Recipients of non-heart beating donor organs.\n\nOther protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Renal Function Measured by Calculated Glomerular Filtration Rate (GFR Calculated According to the Nankivell Formula)","description":"Nankivell's formula for calculated GFR is shown below:\n\nGFR \\[mL/min\\] = 6.7/C + W/4 - UREA/2 - 100/H2+ 35 (25 for females). Where W is body weight at specific visit \\[kg\\], H is height at specific visit \\[m\\], C is the serum concentration of creatinine \\[mmol/L\\], and UREA is the serum concentration of urea \\[mmol/L\\]. UREA was calculated from blood urea nitrogen (BUN) lab data by: UREA = 2.1441\\*BUN. If a GFR value from Nankivell formula was less than 10 \\[mL/min\\], then the value was assigned as 10 \\[mL/min\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":"19.92"},{"groupId":"OG001","value":"69.2","spread":"18.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":"14.61"},{"groupId":"OG001","value":"68.3","spread":"15.13"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biopsy-proven Acute Rejection (BPAR) Episodes, Graft Loss, Death or Loss to Follow-up","description":"Renal biopsies were collected for all cases of suspected acute rejection. For these cases, regardless of initiation of anti-rejection treatment, a graft core biopsy had been performed within 48 hours. These biopsies were listed on the Kidney Allograft Biopsy eCRF and the results used for patient management for BPAR. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant. BPAR, graft loss, death, or loss to follow-up was analyzed by means of frequency tables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Creatinine at Month 6 and 12","description":"serum creatinine summarized by mean and standard deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.1","spread":"31.22"},{"groupId":"OG001","value":"139.1","spread":"47.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.0","spread":"40.28"},{"groupId":"OG001","value":"135.6","spread":"40.61"}]}]}]},{"type":"SECONDARY","title":"Calculated Creatinine Clearance at 6 Month and 12 Month","description":"Creatinine clearance calculated by Cockcroft-Gault formula and summarized by mean, and standard deviation. Cockcroft-Gault formula to calculate Creatinine Clearance (CrCl\\[mL/min\\]) is shown below:\n\nCrCl\\[mL/min\\] = (140 - A) \\* W / (72 \\* C) \\* R. Where A is age at sample date \\[years\\], W is body weight at specific visit \\[kg\\], C is the serum concentration of creatinine \\[mg/dL\\], R = 1 if the patient is male and = 0.85 if female.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":"19.34"},{"groupId":"OG001","value":"63.6","spread":"19.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":"20.50"},{"groupId":"OG001","value":"65.6","spread":"19.24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":55},"commonTop":["Urinary tract infection","Anaemia","Oedema","Oedema peripheral","Pyrexia"]}}}